Recently, Anhui Bocompounds Pharmaceutical Co., Ltd successfully obtained the export sales certificate for moxifloxacin hydrochloride.

Moxifloxacin hydrochloride is a fluoroquinolone antibiotic used to treat community-acquired pneumonia, acute exacerbations of chronic bronchitis, genitourinary infections, and acute sinusitis, with significant efficacy. Jianfeng Beika obtained domestic marketing approval for this product in September 2023. This approval of the export sales certificate signifies that this fourth-generation quinolone broad-spectrum antibacterial raw material has officially obtained WHO international market access qualification and can be legally sold to WHO member states worldwide. Global overseas market demand for this product is stable, with rapid growth in the Asia-Pacific, Middle East, and Africa regions. China and India are the main suppliers of the raw material, and Chinese companies have achieved steady export growth due to their cost and quality advantages.

As a professional raw material manufacturer, Jianfeng Beika adheres to the quality policy of "technological innovation, honesty and trustworthiness, continuous improvement, and customer satisfaction," continuously improving its quality management system and persisting in striving for excellence and continuous improvement. It has won high recognition and satisfaction from customers with its superior quality and excellent service. This certification is an authoritative recognition of Peak North Carolina's comprehensive strength and product quality, which will help the company accelerate its overseas market expansion, promote high-quality Chinese pharmaceutical products to the world, and serve patients worldwide.